Oculis Holding
OCS
9 hedge funds and large institutions have $38.5M invested in Oculis Holding in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
66% more capital invested
Capital invested by funds: $23.2M → $38.5M (+$15.3M)
29% more funds holding
Funds holding: 7 → 9 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.92% less ownership
Funds ownership: 9.54% → 8.63% (-0.92%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
E
Ergoteles
New York
|
+$223K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$44.6K |
| 3 |
Barclays
London,
United Kingdom
|
+$40.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
-$178K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$13.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PBPIA
1
Pivotal bioVenture Partners Investment Advisor
San Francisco,
California
| $29.4M | – | – | – |
|
|
NFGH
2
Nan Fung Group Holdings
Kai Tak,
Hong Kong
| $8.03M | – | – | – |
|
|
CLOS
3
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
| $804K | – | – | – |
|
|
E
4
Ergoteles
New York
| $247K | +$223K | +20,000 | New |
|
|
5
Bank of America
Charlotte,
North Carolina
| $49.3K | +$44.6K | +4,000 | New |
|
|
6
Barclays
London,
United Kingdom
| $44.4K | +$40.2K | +3,602 | New |
|
|
EC
7
Elequin Capital
New York
| $3.7K | – | – | – |
|
|
DCM
8
Dupont Capital Management
Wilmington,
Delaware
| $49 | – | – | – |
|
|
9
UBS Group
Zurich,
Switzerland
| $25 | -$13.5K | -1,210 | -100% |
|
|
HF
10
HRT Financial
New York
| – | -$178K | -24,609 | Closed |
|
OCS Hedge Fund Activity: Q2 2023 in Review
9 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Oculis Holding (OCS) for Q2 2023, worth a combined $38.5M — up 66% from $23.2M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new OCS positions and 1 closed out — a net gain of 2 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Ergoteles, opening a new position worth an estimated $223K. The largest seller was HRT Financial, exiting entirely with an estimated $178K sold.
- 9 institutional investors held Oculis Holding (OCS) as of Q2 2023, up from 7 in Q1 2023.
- Funds reported $38.5M of Oculis Holding stock for Q2 2023, up 66% quarter-over-quarter.
- 3 funds opened new Oculis Holding positions in Q2 2023 and 1 closed out, a net change of +2 holders.
- The largest Oculis Holding buyer in Q2 2023 was Ergoteles, an estimated $223K added.
- The largest Oculis Holding seller in Q2 2023 was HRT Financial, an estimated $178K sold.
Based on aggregated 13F filings for Q2 2023.